Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Biotechnology
Abdera Therapeutics today announced that it has raised $142 million in combined Series A and B financing, with the proceeds to be used for developing transformative radiopharmaceuticals to treat cancer. 21 April 2023
Pharmaceutical
Japanese pharmaceutical giant Takeda is considering selling its Russian plant that produces, Ninlaro (ixazomib), a treatment for patients with multiple myeloma as well as other drugs, according to some local market analysts and Russian media, The Pharma Letters local correspondent reports. 21 April 2023
Biotechnology
Danish biotech Genmab today announced an award in the second arbitration relating to its license agreement with Janssen Biotech. 21 April 2023
Biotechnology
Yet another project focusing on antibody-drug conjugates (ADC) is to get underway, following an agreement between German firm Tubulis and Bristol Myers Squibb. 20 April 2023
Biotechnology
Following a positive advisory committee meeting last month, the US Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq). 20 April 2023
Biotechnology
At present, cancer vaccines are available mainly as part of clinical trials but, with ambitious biotech companies starting to grab the attention of big pharma and other investors with deep pockets, the global market for these immunotherapies is set to expand rapidly. 20 April 2023
Biotechnology
A surprising premature abstract release from the European Hematology Association (EHA) offered the first look at outcomes from CARTITUDE-4, though the abstract has since been removed from the website and may not be the finial information. 20 April 2023
Pharmaceutical
Pharma major GSK has been caught up in a wave of industrial action hitting British companies, as the UK struggles with stubbornly high inflation and a rising cost of living. 19 April 2023
Biotechnology
Engimmune Therapeutics, a biotech developing novel T-cell receptor (TCR)-based therapies, has announced the appointment of Lars Nieba as chief executive. 19 April 2023
Biotechnology
Nektar Therapeutics has reacted to recent setbacks by taking actions expected to significantly reduce future operating expenses and extend its cash runway into the middle of 2026. 19 April 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental new drug application (sNDA) for Lonsurf (trifluridine/tipiracil), Taiho Oncology Inc and Taiho Pharmaceutical, subsidiaries of Japanese drugmaker Otsuka Holdings, have revealed. 19 April 2023
Pharmaceutical
Johnson & Johnson has delivered more than satisfactory financial results from the first quarter of 2023. 18 April 2023
Biotechnology
The US Food and Drug Administration yesterday approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. 18 April 2023
Biotechnology
For EC Awareness month, The Pharma Letter examines the treatment landscape of esophageal cancer (EC), a rare but deadly malignancy that is the sixth most common cause of cancer-related deaths in the world.1 18 April 2023
Biosimilars
South Korean biosimilars company Samsung Bioepis has released the first edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the USA. 18 April 2023
Biotechnology
US biotech Moderna continues to add to the optimism over mRNA-4157 (V940), its investigational cancer vaccine being developed alongside Merck & Co. 17 April 2023
Biotechnology
Merck & Co has announced results from the KEYNOTE-966 trial of Keytruda (pembrolizumab) alongside chemotherapy (gemcitabine and cisplatin) for the first-line treatment of patients with advanced or unresectable biliary tract cancer (BTC). 17 April 2023
Biotechnology
US biotech Incyte and Germany’s MorphoSys have announced five-year follow-up data from the Phase II L-MIND study showing that Monjuvi (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 17 April 2023
Biotechnology
Roche has announced new data from the Phase III IMbrave050 study, combining Tecentriq (atezolizumab) and Avastin (bevacizumab), at the American Association for Cancer Research (AACR) Annual Meeting 2023. 17 April 2023
Biotechnology
Shares of both Denmark-based Genmab and Dutch firm argenx edged up almost 2% after they announced a research partnership, hoping to move the former beyond oncology. 17 April 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze